Business
Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA's Proprietary B cell Select™ and Single Step Cloning Hybridoma Technologies
IPA announces discovery of additional, neutralizing antibodies, developed against SARS-CoV-2, discovered using Ligand Pharmaceuticals' genetically engineered
About this update from Ligand Pharmaceuticals Incorporated
[{"type":"text","content":"IPA announces discovery of additional, neutralizing antibodies, developed against SARS-CoV-2, discovered using Ligand Pharmaceuticals' genetically engineered OmniRat® strains producing human antibodies VICTORIA, July 13, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the \"Company\" or \"IPA\") (TSX.V: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced the identification of additional, human lead candidate antibodies generated against SARS-CoV-2, also demonstrating potent in vitro neutralizing activity, discovered using the Company's B cell Select™ and Single Step Cloning Hybridoma Platforms.\n\nOn June 29, IPA confirmed the identification of a series of lead candidate antibodies demonstrating potent, in vitro neutralizing activity. These functional antibodies were derived from human and llama (VHH) samples using IPA's DeepDisplay™ phage technology. The Company has now added to this lead candidate pool with additional, potent neutralizing antibodies from Ligand Pharmaceuticals' (NASDAQ:LGND) OmniRat® therapeutic human antibody platform as well as wild-type rabbits. The lead neutralizing antibodies announced in the Company's June 29 release, as well as those announced today, are comprised primarily of fully human antibodies (from humans and OmniRat transgenic animals), which are expected to both accelerate timelines to the clinic and to increase the safety and tolerability profiles of the therapeutic candidates.\nThese lead neutralizing antibodies have been moved into manufacturing at the Company for further pre-clinical testing and possible inclusion in the Company's PolyTope™ mAb Therapy to combat the COVID-19 pandemic. The Company is currently exploring business development opportunities with respect to is SARS-CoV-2 antibody programs. The broad range of antibodies being produced at IPA have potential for further use in areas such as additional combination therapies, control antibodies, diagnostics, singular antibody therapies, pre-clinical and clinical batch release assays, and laboratory research.\n\"IPA continues to advance the development of its PolyTope Therapy directed toward SARS-CoV-2 as part of an exceptionally comprehensive pre-clinical therapeutic program ongoing at the Company\", said Dr. Jennifer Bath, CEO and president of IPA, referencing ...